Your English writing platform
Discover LudwigExact(19)
There is a good possibility that the CAPITA trial results will be inconclusive.
These effects stretch beyond the hospitalization period, as covered in the CAPiTA trial.
As part of the CAPiTA trial, patients with a clinical suspicion of CAP are tracked in 56 Dutch sentinel hospitals.
At this time, we cannot know whether the CAPITA trial will yield useful results, but there are reasons for doubt.
The infrastructure of the CAPiTA trial offers a unique opportunity for prospective collection of health outcomes, QoL and cost data of patients hospitalized with CAP.
The efficacy of the PCV-13 in the elderly has been investigated according to these requirements in a large RCT known as the CAPiTA trial [ 12, 13].
Similar(41)
Investigators in the Netherlands will soon conclude their randomized, placebo-controlled clinical trial (CAPITA) of PCV13 vaccination in 85 000 community-dwelling persons ≥65 y of age.
The Ohio State University is among the country's top public research institutions at #7. Ohio is ranked in the top eight for states conducting clinical trials, including conducting the most clinical trials per capita.
To determine the accurateness of detecting community-acquired pneumonia (CAP) in the Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA), a community-based, double-blind, randomized placebo-controlled trial in which the needed to treat (NNT) for prevention of vaccine-type pneumococcal CAP was 1,007 [95% confidence interval (CI): 613, 2,646].
The efficacy of PCV13 in the prevention of a first episode of vaccine-serotype-specific pneumococcal CAP was studied in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) [ 109] that was recently completed.
The results of the Community Acquired Pneumonia IMmunization Trial in Adults (CAPITA), a large-scale randomized trial investigating efficacy of PCV13 in adults above 65 years of age (http://clinicaltrials.gov/show/NCT00744263) may provide some data to this effect, but will still not be directly applicable to adolescent risk groups.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com